Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients.
Read full article >>
Other news & events
- News12.05.2026
#ASCO26 - Radiopharmaceutical Therapy in Oncology: Practical Integration for Practicing Oncologists
Read more - News11.05.2026
Oncidium foundation partners with Curium to expand access to Radioligand Therapy worldwide
Read more - News22.04.2026
Addressing Barriers to Radioligand Therapy at the European Parliament
Read more
